Artículos por temáticas

PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients

Wang HY, Pei Z, Lee KC, Lopez-Brignoni E, Nikolov B, Crowley CA, Marsman MR, Barbier R, Friedmann N, Burns LH.

J Prev Alzheimers Dis. 2020;7(4):256-264. doi: 10.14283/jpad.2020.6.

Boosting the autophagy-lysosomal pathway by phytochemicals: A potential therapeutic strategy against Alzheimer's disease

Nourbakhsh F, Read MI, Barreto GE, Sahebkar A.

IUBMB Life. 2020 Nov;72(11):2360-2281. doi: 10.1002/iub.2369. Epub 2020 Sep 7.

In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease

Briels CT, Stam CJ, Scheltens P, Bruins S, Lues I, Gouw AA.

Clin Neurophysiol. 2020 Jan;131(1):88-95. doi: 10.1016/j.clinph.2019.09.014. Epub 2019 Nov 4.

The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP)

Takemoto M, Ohta Y, Hishikawa N, Yamashita T, Nomura E, Tsunoda K, Sasaki R, Tadokoro K, Matsumoto N, Omote Y, Abe K.

J Alzheimers Dis. 2020;76(2):769-772. doi: 10.3233/JAD-200247.

Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer's disease

Arora D, Bhatt S, Kumar M, Vattikonda HDC, Taneja Y, Jain V, Joshi V, Gali CC.

Curr Pharm Des. 2020;26(27):3281-3299. doi: 10.2174/1381612826666200331085854.

The Glucose Metabolic Pathway as A Potential Target for Therapeutics: Crucial Role of Glycosylation in Alzheimer's Disease

Bukke VN, Villani R, Archana M, Wawrzyniak A, Balawender K, Orkisz S, Ferraro L, Serviddio G, Cassano T.

Int J Mol Sci. 2020 Oct 19;21(20):7739. doi: 10.3390/ijms21207739.

Microbial acetylcholinesterase inhibitors for Alzheimer's therapy: recent trends on extraction, detection, irradiation-assisted production improvement and nano-structured drug delivery

Zaki AG, El-Sayed ER, Abd Elkodous M, El-Sayyad GS.

Appl Microbiol Biotechnol. 2020 Jun;104(11):4717-4735. doi: 10.1007/s00253-020-10560-9. Epub 2020 Apr 13.

Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer's Disease

Fülöp T, Munawara U, Larbi A, Desroches M, Rodrigues S, Catanzaro M, Guidolin A, Khalil A, Bernier F, Barron AE, Hirokawa K, Beauregard PB, Dumoulin D, Bellenger JP, Witkowski JM, Frost E.

CNS Drugs. 2020 Jul;34(7):673-695. doi: 10.1007/s40263-020-00737-1.

Use of Biodegradable, Chitosan-Based Nanoparticles in the Treatment of Alzheimer's Disease

Manek E, Darvas F, Petroianu GA.

Molecules. 2020 Oct 21;25(20):4866. doi: 10.3390/molecules25204866.

A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?

Esterline R, Oscarsson J, Burns J.

Int Rev Neurobiol. 2020;155:113-140. doi: 10.1016/bs.irn.2020.03.018. Epub 2020 Aug 11.

Depression-an underrecognized target for prevention of dementia in Alzheimer's disease

Dafsari FS, Jessen F.

Transl Psychiatry. 2020 May 20;10(1):160. doi: 10.1038/s41398-020-0839-1.

The Nerve to Give BACE Inhibitors a Second Chance?

Baloh RH.

Neurotherapeutics. 2020 Jul;17(3):966-967. doi: 10.1007/s13311-020-00876-9.

M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?

Scarpa M, Hesse S, Bradley SJ.

Adv Pharmacol. 2020;88:277-310. doi: 10.1016/bs.apha.2019.12.003. Epub 2020 Jan 27.

Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?

Moss DE.

Int J Mol Sci. 2020 May 13;21(10):3438. doi: 10.3390/ijms21103438.

Non-steroidal Anti-inflammatory Drugs as Candidates for the Prevention or Treatment of Alzheimer's Disease: Do they Still Have a Role?

Villarejo-Galende A, González-Sánchez M, Blanco-Palmero VA, Llamas-Velasco S, Benito-León J.

Curr Alzheimer Res. 2020;17(11):1013-1022. doi: 10.2174/1567205017666201127163018.